Molecular Formula | C18H22N2O2S |
Molar Mass | 330.44 |
Density | 1.1453 (rough estimate) |
Melting Point | 85~88℃ |
Boling Point | 427.8±55.0 °C(Predicted) |
Appearance | neat |
pKa | 1.22±0.10(Predicted) |
Storage Condition | 0-6°C |
Refractive Index | 1.6000 (estimate) |
In vitro study | Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR). Pyributicarb is found to increase the CYP3A4 reporter activity at 0.1 to 1 μM more strongly than typical CYP3A4 inducer rifampicin. Expression of hPXR-siRNA clearly diminishes the Pyributicarb-stimulated CYP3A4 reporter activity in 3-1-10 cells and decreases the endogenous CYP3A4 mRNA levels in HepG2 cells. Pyributicarb induces luciferase transcription via hPXR at low concentrations in the order of 10 nM. The relative potency of Pyributicarb for hPXR is 8.6-fold that of rifampicin (RIF). |
In vivo study | Pyributicarb causes enhancement of CYP3A4 -derived reporter activity in mouse livers introduced with hPXR by adenovirus. |
Hazard Symbols | N - Dangerous for the environment |
Risk Codes | 50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
Safety Description | 61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
UN IDs | UN 3077 9 / PGIII |
WGK Germany | 3 |
RTECS | XK4962000 |
HS Code | 29333990 |
biological activity | Pyributicarb is a carbamate herbicide, which is an effective activator of CYP3A4 gene and human pregnane X receptor (hPXR). |
target | CYP3A4, hPXR |
in vitro research | Pyributicarb, a carbamate-type herbicide, is a potent activator of both CYP3A4 gene and human pregnane X receptor (hPXR). Pyributicarb is found to increase the CYP3A4 reporter activity at 0.1 to 1 μM more strongly than typical CYP3A4 inducer rifampicin. Expression of hPXR-siRNA clearly diminishes the Pyributicarb-stimulated CYP3A4 reporter activity in 3-1-10 cells and decreases the endogenous CYP3A4 mRNA levels in HepG2 cells. Pyributicarb induces luciferase transcription via hPXR at low concentrations in the order of 10 nm. The relative potency of Pyributicarb for hPXR is 8.6-fold that of rifampicin (RIF). |
in vivo studies | Pyributicarb uses enhancement of CYP3A4 -derived reporter activity in mouse lives introduced with hPXR by adenovirus. |